By owais When teams compare tray solutions, they’re not just picking a plastic — they’re choosing how a device will age under gamma irradiation and what contaminants might migrate into the product. Recent conversations at the shanghai medical expo highlighted that small differences in polymer grade and tray geometry produce measurable changes in extractables and leachables. That real-world lens — from a major China medical exhibition — anchors what follows: practical contrasts, backed by testing and factory experience, so design and procurement decisions avoid costly surprises.
Start at the raw material. Semi-crystalline polymers such as polypropylene respond to gamma irradiation differently than amorphous materials like polycarbonate; additives and stabilizers can break down and generate leachables. Compare options on three axes: intrinsic chemistry, additive load, and processing conditions. Industry terms that matter here: gamma irradiation, sterilization validation, and biocompatibility. For certification, teams typically reference ISO 10993 series — notably ISO 10993-1 (Evaluation and testing within a risk management process), ISO 10993-5 (Tests for in vitro cytotoxicity), and ISO 10993-10 (Tests for irritation and skin sensitization). Knowing which sub-parts apply avoids overtesting or missing a critical assay.
Tray walls, ribs, and corners change surface area-to-volume ratios and therefore the extractables profile. Thinner sections heat and degrade differently during sterilization, so design choices influence chemistry no less than polymer selection. Validation workflows should include extractables screening and targeted leachables under worst-case conditions. Common standards used in labs include USP <661> for plastics; sterilization validation often references ISO 11137 parts 1–3. Also define retention sample testing requirements up front — for example, a 14-day bioburden incubation limit for retention samples when validating microbial endpoints — so you don’t delay regulatory submissions later.
Lab bench testing isolates variables; in-field runs catch supplier and process variation. Here’s a short comparison:
- Lab bench: controlled extractables profile, accelerated aging, analytical chemistry (GC–MS, LC–MS).
- In-field: production-run sampling, real sterilization cycles, packaging interactions.
- Hybrid: pilot runs that combine bench-derived worst-case conditions with full-scale production to confirm assumptions.
Each path has trade-offs in cost and time. Most teams gain confidence by starting with lab screening, then confirming on pilot runs at supplier sites — especially those who visited booths at recent Shanghai shows and saw actual production lines.
One repeated error is relying solely on supplier declarations for additive stability — perfecto on paper, risky in practice. Another is designing trays for minimum material use without testing mechanical performance post-irradiation. The fixes are straightforward: require material traceability, demand gamma-aging data, and include post-sterilization mechanical tests in your protocol. — Also, document expected service temperatures and include migration assays that mirror those conditions.
Compare the following metrics when you evaluate vendors: analytical extractables profiles, sterilization validation records (ISO 11137-1/2/3), and biocompatibility evidence per ISO 10993 subparts. Add production controls like lot-to-lot variability data and retention sampling plans. Weight regulatory alignment and supplier transparency equally with price — cheap materials that spike leachables after irradiation create downstream risk. Mentioning the China medical exhibition networks here makes sense: those shows let you see supplier QA systems firsthand.
1) Validate under worst-case conditions: include accelerated gamma-aging and post-sterilization chemistry to predict leachables. 2) Require documented ISO and USP references from suppliers: ISO 10993-1, ISO 10993-5, ISO 10993-10 and USP <661> where plastics are involved. 3) Insist on retention sampling and clear incubation windows — for microbial endpoints, adopt a 14-day bioburden incubation limit for your retention plan. These rules give measurable gates for acceptance and reduce rework.
Medtec adds value by connecting design teams with vetted suppliers and live validation data — a practical bridge from lab findings to production reality. — Final thought: choose evidence over assumptions.
Admin